A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
Article Abstract:
The final results of the European Study Group for Pancreatic Cancer 1 Trial are reported and the interim results are updated. It is concluded that adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer
Article Abstract:
A study reports on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. Rofecoxib is found to be associated with an increased frequency of adverse cardiovascular events with a median study treatment of 7.4 months' duration.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Adjuvant therapy for pancreatic cancer-the debate continues
Article Abstract:
An updated and improved analysis of the European Study Group for Pancreatic Cancer (ESPAC-1) trial, the largest randomized trial of adjuvant therapy for pancreatic cancer, is reported. The attempts made to correct some of the limitations of the previous report are discussed.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
- Abstracts: Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: Its role in preventing HIV infection in infants
- Abstracts: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Clues for new therapeutics in osteoporosis